Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Average Recommendation of “Buy” by Analysts

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has received a consensus recommendation of “Buy” from the six research firms that are currently covering the stock, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $29.50.

CPRX has been the topic of several analyst reports. Truist Financial raised their price objective on Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the stock a “buy” rating in a report on Friday, August 9th. HC Wainwright boosted their target price on shares of Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the company a “buy” rating in a report on Monday, August 12th. StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 9th. Citigroup upped their price objective on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $29.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, June 6th.

Catalyst Pharmaceuticals Trading Down 2.0 %

Shares of CPRX stock opened at $19.56 on Monday. The company has a market capitalization of $2.31 billion, a price-to-earnings ratio of 36.22, a PEG ratio of 3.27 and a beta of 0.75. The firm has a 50-day moving average price of $19.22 and a 200 day moving average price of $16.95. Catalyst Pharmaceuticals has a twelve month low of $11.55 and a twelve month high of $21.67.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.13. Catalyst Pharmaceuticals had a net margin of 15.69% and a return on equity of 27.77%. The business had revenue of $122.71 million for the quarter, compared to the consensus estimate of $111.76 million. As a group, research analysts predict that Catalyst Pharmaceuticals will post 1.82 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Carmen Jeffrey Del sold 36,058 shares of the company’s stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $18.42, for a total value of $664,188.36. Following the completion of the sale, the insider now owns 12,369 shares of the company’s stock, valued at $227,836.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, insider Steve Miller sold 150,000 shares of Catalyst Pharmaceuticals stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $20.35, for a total transaction of $3,052,500.00. Following the sale, the insider now owns 675,124 shares of the company’s stock, valued at approximately $13,738,773.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Carmen Jeffrey Del sold 36,058 shares of the business’s stock in a transaction on Friday, August 9th. The stock was sold at an average price of $18.42, for a total transaction of $664,188.36. Following the completion of the transaction, the insider now owns 12,369 shares in the company, valued at approximately $227,836.98. The disclosure for this sale can be found here. In the last three months, insiders sold 201,058 shares of company stock valued at $4,018,188. Company insiders own 11.00% of the company’s stock.

Institutional Trading of Catalyst Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Point72 Asia Singapore Pte. Ltd. purchased a new position in Catalyst Pharmaceuticals in the second quarter valued at about $153,000. PVG Asset Management Corp purchased a new position in shares of Catalyst Pharmaceuticals during the 2nd quarter valued at approximately $183,000. Point72 Asset Management L.P. grew its position in shares of Catalyst Pharmaceuticals by 47.9% during the second quarter. Point72 Asset Management L.P. now owns 618,296 shares of the biopharmaceutical company’s stock worth $9,577,000 after buying an additional 200,370 shares in the last quarter. Quarry LP increased its stake in shares of Catalyst Pharmaceuticals by 170.0% in the second quarter. Quarry LP now owns 16,334 shares of the biopharmaceutical company’s stock worth $253,000 after buying an additional 10,284 shares during the last quarter. Finally, Algert Global LLC acquired a new stake in Catalyst Pharmaceuticals in the second quarter valued at $165,000. 79.22% of the stock is owned by hedge funds and other institutional investors.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.